Dr. Reddy's Laboratories enters into licensing agreement with XenoPort

28 Mar 2016 Evaluate

Dr. Reddy's Laboratories and XenoPort, Inc have entered into a license agreement pursuant to which the company will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity -- XP23829. The company is planning to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).

Under the terms of the agreement, the company will receive exclusive U.S. rights to develop and commercialize XP23829 for all indications. In exchange for these rights, XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials to the company. XenoPort will also be eligible to receive up to $190 million upon the achievement by the company of certain regulatory milestones which could be achieved over a period of several years. In addition, XenoPort will be eligible to receive up to $250 million upon the achievement of commercial milestones and up to mid-teens royalty payments based on potential net sales of XP23829 in the United States.

Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1166.90 0.45 (0.04%)
20-Jan-2026 15:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1381.00
Zydus Lifesciences 872.95
Lupin 2160.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×